Samil Pharmaceutical Co., Ltd.
http://eng.samil-pharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Samil Pharmaceutical Co., Ltd.
Australian Teeth Whitener Marketer Frowns On Industry Self-Regulation Referencing US Laws
HiSmile appeals NAD recommendation following review on P&G challenge to discontinue ad claims on its website and in social media videos stating peroxide-containing whitening products are “painful” or cause pain, break down and impact gums and teeth, or “damage” gums.
Lumineux Called For Foul In Teeth Whitening Claim Review For Implying ‘Harm’ From Crest Whitestrips
National Advertising Division recommends Oral Essentials discontinue claims on packaging that Lumineux strips are "first on the market that are delicious and clinically proven to whiten teeth as well as the leading brand, without the harm associated with bleaches.”
J&J Has Kenvue IPO Roadshow In One Lane, Potentially Long Road For Talc Litigation In Other
Roadshow stated for IPO planned for before end of 2023 of 151.2m shares of Kenvue common stock currently expected at between $20 and $23 per share. Analysts positive on IPO but caution launch wouldn’t come problem-free.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice